CLINICAL AND PROGNOSTIC SIGNIFICANCE OF PYROPTOSIS MARKERS IN THE PROGRESSION OF AXIAL SPONDYLOARTHRITIS
Abstract
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease predominantly affecting the axial skeleton, including the spine and sacroiliac joints. Pyroptosis — a caspase-dependent pro-inflammatory form of programmed cell death — plays a significant role in the pathogenesis of axSpA. Recent evidence suggests that activation of the NLRP3 inflammasome, elevated levels of IL-1β and IL-18, and cleavage of gasdermin D may correlate with disease progression and inflammatory activity. This review discusses the relationship between pyroptosis markers and clinical parameters, radiological progression, and inflammatory activity in axSpA. Investigation of pyroptosis markers may have considerable value for early diagnosis and the development of targeted therapeutic strategies.
References
1. Baeten D., Sieper J., Braun J., et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48.
2. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19(1):41–52.
3. Breban M., Tap J., Leboime A., et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76(9):1614–22.
4. Brown M.A., Kennedy L.G., MacGregor A.J., et al. Susceptibility to ankylosing spondylitis in twins. Arthritis Rheum. 1997;40(10):1823–8.
5. Chen J., Zhao Q., Wei G., et al. NLRP3 inflammasome activation and IL-1β production in ankylosing spondylitis. Clin Exp Rheumatol. 2019;37(2):246–53.
6. Coll R.C., Robertson A.A., Chae J.J., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–55.
7. Gul A., Tugal-Tutkun I., Dinarello C.A., et al. Interleukin-1β-regulated inflammation and disease activity in axial spondyloarthritis. Ann Rheum Dis. 2021;80(1):95–103.
8. Ito M., Yurube T., Kanda F., et al. Caspase-1 activity in peripheral blood monocytes correlates with disease activity in ankylosing spondylitis. Clin Immunol. 2021;224:108666.
9. Khalmetova, F. I., Akhmedov, K. S., Buranova, S. N., Rakhimova, M. B., Rakhimov, S. S., & Abdurakhimova, L. A. (2023). Immunological Features of Reactive Arthritis of Various Etiologies. Journal of Coastal Life Medicine, 11, 1322-1325.
10. Li X., Zhang M., Feng D., et al. Gasdermin D as a biomarker of disease activity and treatment response in axial spondyloarthritis. Rheumatology (Oxford). 2023;62(4):1420–7.
11. Liu Y., Fang Y., Chen X., et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2021;6(55):eabb7827.
12. Maksymowych W.P., van der Heijde D., Sieper J., et al. Baseline and on-treatment factors predictive of treatment response in axial spondyloarthritis. RMD Open. 2021;7(2):e001590.
13. McGonagle D., Sharif K., O'Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
14. Mesquida M., Molins B., Llorenç V., et al. Interleukin-18 serum levels in axial spondyloarthritis-associated uveitis: correlation with ocular disease activity and extra-articular manifestations. Invest Ophthalmol Vis Sci. 2018;59(11):4513–9.
15. Rakhimova, M., Akhmedov, K., Buranova, S., & Tursunova, L. (2022). Еvaluationofcardiovascular events in patients with ankylosing spondylitis after COVID-19
16. Ramiro S., Stolwijk C., van Tubergen A., et al. Evolution of radiographic damage in ankylosing spondylitis: a 12-year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015;74(1):52–9.
17. Ranganathan V., Gracey E., Brown M.A., et al. Pathogenesis of ankylosing spondylitis — recent advances and future directions. Nat Rev Rheumatol. 2017;13(6):359–67.
18. Ruiz de Morales J.M., Juanola X., de Vicuña R.G., et al. Fundamental role of neutrophils in the pathogenesis of spondyloarthropathies. Autoimmun Rev. 2018;17(6):605–10.
19. Schett G., Lories R.J., D'Agostino M.A., et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731–41.
20. Shi J., Zhao Y., Wang K., et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5.
21. Sieper J., Listing J., Poddubnyy D., et al. Effect of continuous versus on-demand treatment with diclofenac over 2 years on radiographic progression of the sacroiliac joints in patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(8):1511–7.
22. Swanson K.V., Deng M., Ting J.P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–89.
23. Taurog J.D., Chhabra A., Colbert R.A. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563–74.
24. Wang J., Zhu X., He Y., et al. Inflammasome activation and pyroptosis in axial spondyloarthritis: immunohistochemical analysis of entheseal tissue. Arthritis Res Ther. 2022;24(1):113.
25. Ye Y., Jin T., Zhang X., et al. Gasdermin D cleavage products correlate with radiological progression in ankylosing spondylitis: a two-year longitudinal study. J Inflamm Res. 2023;16:1789–98.
26. Zeng C., Wang R., Tan H. Role of pyroptosis in cardiovascular diseases and its therapeutic implications. Int J Biol Sci. 2019;15(7):1345–57.
27. Zhao J., Lin X., Meng D., et al. NLRP3 inflammasome genetic polymorphisms and susceptibility to ankylosing spondylitis. J Rheumatol. 2020;47(6):853–60.
28. Zhou B., Abbott D.W. Gasdermin E permits interleukin-1 beta release in distinct sublytic and pyroptotic phases. Cell Rep. 2021;35(2):108998.
29. Абдурахимов, А. Г., & Халметова, Ф. И. (2023). Нестероидные противовоспалительные препараты у пациентов с деформирующим остеоартрозом и артериальной гипертензией: анализ влияния целекоксиба и мелоксикама на антигипертензивные средства. Оптимизация лечения. Атеросклероз, 19(3), 186-187.
30. Рахимова, М. Б., Ахмедов, Х. С., & Халметова, Ф. И. (2025). ОЦЕНКА ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ.
31. Шовкатова, М. Н., & Рахимова, М. Б. (2025). ИСКУССТВЕННЫЙ ИНТЕЛЛЕКТ В ЦИФРОВОЙ СТРАТИФИКАЦИИ И ДИНАМИЧЕСКОМ КОНТРОЛЕ СЕРДЕЧНО-СОСУДИСТОГО РИСКА У БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ И РЕВМАТОИДНЫМ АРТРИТОМ. FARS International Journal of Education, Social Science & Humanities., 13(12), 7-14.
